Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4269 USD | +6.25% | -1.13% | -71.35% |
May. 23 | UBS Adjusts American Well Price Target to $0.60 From $1.50, Maintains Neutral Rating | MT |
May. 01 | Transcript : American Well Corporation, Q1 2024 Earnings Call, May 01, 2024 |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-71.35% | 127M | C- | ||
+118.20% | 4.17B | - | ||
+78.57% | 584M | - | - | |
+3.15% | 445M | - | ||
-25.18% | 94.34M | - | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AMWL Stock
- Ratings American Well Corporation